Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Artelo Biosciences, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- −4 vs. Q4 2021
- Shares held
- 1.47M
- −432.4K (−22.8%) vs. Q4 2021
- Total value
- $659.0K
- −$325.0K (−33.0%) vs. Q4 2021
- New holders
- 4
- 7 more added
- Sold out
- 8
- 4 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $132.0K |
| Q1 2026 | 11 | $829.9K |
| Q4 2025 | 10 | $120.6K |
| Q3 2025 | 9 | $151.7K |
| Q2 2025 | 9 | $220.1K |
| Q1 2025 | 8 | $75.8K |
| Q4 2024 | 6 | $36.6K |
| Q3 2024 | 5 | $25.6K |
| Q2 2024 | 6 | $35.7K |
| Q1 2024 | 7 | $37.2K |
| Q4 2023 | 7 | $34.3K |
| Q3 2023 | 8 | $76.4K |
| Q2 2023 | 6 | $78.4K |
| Q1 2023 | 7 | $110.8K |
| Q4 2022 | 8 | $337.9K |
| Q3 2022 | 9 | $464.0K |
| Q2 2022 | 15 | $442.8K |
| Q1 2022 | 18 | $659.0K |
| Q4 2021 | 22 | $984.0K |
| Q3 2021 | 17 | $1.57M |
| Q2 2021 | 20 | $3.29M |
| Q1 2021 | 15 | $2.17M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Artelo Biosciences, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Creative Financial Designs Inc | 1,075 | $0 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 260 | $0 | 0.00% | +110+73.3% | Added |
| Morgan Stanley | 300 | $0 | 0.00% | +298+14,900.0% | Added |
| Susquehanna International Group, LLP | 10,932 | $5.00K | 0.00% | −5,352−32.9% | Reduced |
| State Street Corp | 13,039 | $6.00K | 0.00% | +2,639+25.4% | Added |
| Keystone Wealth Partners | 15,000 | $7.00K | 0.00% | +15,000 | New |
| Two Sigma Securities, LLC | 18,227 | $8.00K | 0.00% | −6,395−26.0% | Reduced |
| UBS Group AG | 18,283 | $8.00K | 0.00% | +18,283 | New |
| Tower Research Capital LLC (TRC) | 19,723 | $9.00K | 0.00% | +14,262+261.2% | Added |
| Virtu Financial LLC | 23,801 | $11.0K | 0.00% | −156,481−86.8% | Reduced |
| HighTower Advisors, LLC | 26,000 | $12.0K | 0.00% | +10,000+62.5% | Added |
| HRT Financial LP | 27,952 | $12.0K | 0.00% | +27,952 | New |
| Northern Trust Corp | 62,521 | $28.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 86,603 | $39.0K | 0.00% | 00.0% | Unchanged |
| Snowden Capital Advisors LLC | 110,000 | $49.0K | 0.00% | +110,000 | New |
| Geode Capital Management, LLC | 167,826 | $75.0K | 0.00% | +5,076+3.1% | Added |
| Renaissance Technologies LLC | 182,619 | $82.0K | 0.00% | +73,819+67.8% | Added |
| Vanguard Group Inc | 683,896 | $308.0K | 0.00% | −207,027−23.2% | Reduced |
| Kepos Capital LP | 0 | $0 | 0.00% | −200,000−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −78,586−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −27,470−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −16,000−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −11,977−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −46−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −65−100.0% | Sold out |
| Global Wealth Management Investment Advisory, Inc. | 0 | $0 | 0.00% | −475−100.0% | Sold out |